In vitro targeted photodynamic therapy with a pyropheophorbide‐a conjugated inhibitor of prostate‐specific membrane antigen
- 13 January 2009
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 69 (6) , 585-594
Abstract
BACKGROUND: The lack of specific delivery of photosensitizers (PSs), represents a significant limitation of photodynamic therapy (PDT) of cancer. The biomarker prostate‐specific membrane antigen (PSMA) has attracted considerable attention as a target for imaging and therapeutic applications for prostate cancer. Although recent efforts have been made to conjugate inhibitors of PSMA with imaging agents, there have been no reports on PS‐conjugated PSMA inhibitors for targeted PDT of prostate cancer. The present study focuses on the use of a PSMA inhibitor‐conjugate of pyropheophorbide‐a (Ppa‐conjugate 2) for targeted PDT to achieve apoptosis in PSMA+ LNCaP cells.METHODS: Confocal laser scanning microscopy with a combination of nuclear staining and immunofluorescence methods were employed to monitor the specific imaging and PDT‐mediated apoptotic effects on PSMA‐positive LNCaP and PSMA‐negative (PC‐3) cells.RESULTS: Our results demonstrated that PDT‐mediated effects by Ppa‐conjugate 2 were specific to LNCaP cells, but not PC‐3 cells. Cell permeability was detected as early as 2 hr by HOE33342/PI double staining, becoming more intense by 4 hr. Evidence for the apoptotic caspase cascade being activated was based on the appearance of poly‐ADP‐ribose polymerase (PARP) p85 fragment. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay detected DNA fragmentation 16 hr post‐PDT, confirming apoptotic events.CONCLUSIONS: Cell permeability by HOE33342/PI double staining as well as PARP p85 fragment and TUNEL assays confirm cellular apoptosis in PSMA+ cells when treated with PS‐inhibitor conjugate 2 and subsequently irradiated. It is expected that the PSMA targeting small‐molecule of this conjugate can serve as a delivery vehicle for PDT and other therapeutic applications for prostate cancer. Prostate 69:585–594, 2009.Keywords
This publication has 70 references indexed in Scilit:
- Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)Journal of Medicinal Chemistry, 2008
- N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate CancerClinical Cancer Research, 2008
- The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigenBioorganic & Medicinal Chemistry, 2007
- Substrate specificity of prostate-specific membrane antigenBioorganic & Medicinal Chemistry, 2007
- Peptide-Based Pharmacomodulation of a Cancer-Targeted Optical Imaging and Photodynamic Therapy AgentBioconjugate Chemistry, 2007
- Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid TumorsJournal of Clinical Oncology, 2007
- Sphingomyelins suppress the targeted disruption of lysosomes/endosomes by the photosensitizer NPe6 during photodynamic therapyBiochemical Journal, 2005
- Microfluidic System for Studying the Interaction of Nanoparticles and Microparticles with CellsAnalytical Chemistry, 2005
- Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigenExpert Opinion on Therapeutic Targets, 2005
- Photodynamic Therapy with Pyropheophorbide-a Methyl Ester in Human Lung Carcinoma Cancer Cell: Efficacy, Localization and Apoptosis¶Photochemistry and Photobiology, 2002